A Phase II Safety and Tolerability Study With SEN0014196

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2012
The principal aim of this study is to obtain safety and tolerability data when SEN0014196 is administered orally over 12 weeks to male and female patients with Huntington\'s Disease.
Epistemonikos ID: c18ffdfa7fd797fc4cb36e6d831857cb49ee4f92
First added on: Mar 30, 2022